Medpace price target raised to $270 from $260 at Baird

Baird raised the firm’s price target on Medpace to $270 from $260 and keeps a Neutral rating on the shares. The firm said they cintinue to warm to the name as they believe the core story remains intact however tough comparisons in 3Q, negative investor sentiment around R&D broadly, recent executive selling, and likely conclusion to notable support via share repurchase leaves them tentative.